Clinical research in Parkinson’s disease (PD) is often slowed by long timelines, noisy outcomes, and the need for large patient cohorts. At Unlearn, we’re helping to change that. Our AI-powered digital twins enable sponsors to design faster, more efficient PD trials, delivering earlier insights, greater power, and smaller sample sizes.

Our PD-specific Digital Twin Generator (PD DTG v1.2) forecasts each participant’s clinical outcomes under placebo, helping sponsors boost power and reduce trial burden. Built using data from more than 2,100 participants and over 9,500 clinical visits, PD DTG v1.2 is powered by Neural Boltzmann Machines—a proprietary machine learning architecture optimized for probabilistically modeling complex, multivariate clinical time-series data.

Unlike simple baseline covariate adjustment methods, Unlearn’s digital twins provide longitudinal, individualized forecasts across every time point of the trial. Each participant’s digital twin captures detailed clinical trajectories—not just a single predicted outcome—offering actionable insights across trial planning, design, and analysis.

By integrating digital twins into trial design and analysis, sponsors can:

• Reduce sample sizes by up to 23% in Phase 2 and 12% in Phase 3
• Reduce control arm sizes by up to 38% in Phase 2 and 22% in Phase 3
• Increase power by up to 9.3% in Phase 2 and 5.1% in Phase 3
• Increase the chances of detecting meaningful treatment effects by approximately 11% in Phase 2
• Strengthen endpoint sensitivity and enable earlier, more confident go/no-go decisions

We recently shared this work at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, where we presented a case study applying Bayesian PROCOVA to optimize Phase 2 and Phase 3 trial designs in Parkinson’s disease.

Whether you’re running an early proof-of-concept study or preparing for pivotal Phase 3 trials, Unlearn’s digital twins provide a powerful new tool to accelerate timelines, improve precision, and bring meaningful therapies to people living with Parkinson’s disease.

Learn more about our Parkinson’s Disease capabilities here.